Renalytix AI Plc (LON: RENX) has released its results for the year ended 30 June 2020.
- The year marked the period of considerable progress for the company in advancing the processes of regulatory and reimbursement consent and preparing for commercialisation.
- The company during the year invested $2.9 million in assay development, laboratory equipment and clinical validation. The company so far has invested $4.5 million since inception.
- The company was having cash and equivalents of $13.3 million as on 30 June 2020, ahead of the July 2020 Nasdaq dual-listing and associated financing.
- On 27 October 2020, the stocks of the company increased by 1.09% from its previous closing, hovering at around GBX 465.00 at 08:14 AM GMT+1.